Soligenix Appoints Former White House Economic Advisor Tomas Philipson to Strategic Role
TL;DR
Soligenix gains strategic advantage by appointing former White House economic advisor Tomas Philipson to help advance HyBryte through Phase 3 trials and commercialization.
Soligenix appointed healthcare policy expert Tomas Philipson as Strategic Advisor to leverage his government and economic expertise in advancing rare disease treatments through regulatory pathways.
This appointment supports Soligenix's mission to bring treatments for rare diseases with unmet medical needs to market, improving patient outcomes worldwide.
A former White House economic advisor joins Soligenix to help commercialize HyBryte, a novel photodynamic therapy for cutaneous T-cell lymphoma using visible light.
Found this article helpful?
Share it with your network and spread the knowledge!
Soligenix Inc. has appointed Tomas J. Philipson, PhD, a prominent healthcare policy expert and former acting chairman of the White House Council of Economic Advisers, as a strategic advisor. The appointment comes as the late-stage biopharmaceutical company advances its lead product candidate HyBryte through confirmatory Phase 3 trials for cutaneous T-cell lymphoma.
Dr. Philipson brings extensive experience in U.S. economic and healthcare policy, having previously advised the Food and Drug Administration, Centers for Medicare & Medicaid Services, and major healthcare initiatives. His background includes academic, business, and government roles, and he currently serves as Managing Partner of MEDA Ventures while holding positions on several corporate boards. Soligenix CEO Christopher J. Schaber stated that Philipson's expertise and relationships will be instrumental during this critical phase of the company's development.
The strategic appointment signals Soligenix's commitment to navigating complex regulatory pathways as it prepares for potential commercialization of HyBryte, a novel photodynamic therapy that uses safe visible light for treating cutaneous T-cell lymphoma. With the successful completion of a second Phase 3 study, the company plans to seek regulatory approvals worldwide. Additional information about the company's developments is available at https://ibn.fm/SNGX.
Dr. Philipson expressed his enthusiasm for supporting Soligenix's mission to bring treatments for rare diseases with unmet medical needs to market. The company's pipeline extends beyond HyBryte, including development programs for synthetic hypericin expansion into psoriasis, innate defense regulator technology for inflammatory diseases, and multiple vaccine candidates through its Public Health Solutions business segment.
The significance of this appointment extends beyond corporate strategy, potentially impacting patient access to novel treatments for rare conditions. Philipson's government experience and understanding of healthcare economics could help streamline the path to market for therapies addressing underserved medical needs. His involvement may also enhance investor confidence as Soligenix progresses toward potential commercialization milestones.
Soligenix's Public Health Solutions division has received government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. These partnerships underscore the broader public health importance of the company's vaccine development programs targeting threats such as ricin toxin, filoviruses, and COVID-19. More details about the recent appointment can be found in the full press release at https://ibn.fm/M7YEd.
Curated from InvestorBrandNetwork (IBN)
